Celldex Therapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Celldex Therapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $1.76M | Mar 7, 2019 |
| FY2018 | Sep 30, 2018 | $941.0K | Mar 7, 2019 |
| FY2018 | Jun 30, 2018 | $2.76M | Mar 7, 2019 |
| FY2018 | Mar 31, 2018 | $4.07M | Mar 7, 2019 |
| FY2017 | Dec 31, 2017 | $3.46M | Mar 7, 2018 |
| FY2017 | Sep 30, 2017 | $3.92M | Mar 7, 2018 |
| FY2017 | Jun 30, 2017 | $3.83M | Mar 7, 2018 |
| FY2017 | Mar 31, 2017 | $1.53M | Mar 7, 2018 |
| FY2016 | Dec 31, 2016 | $1.87M | Mar 14, 2017 |
| FY2016 | Sep 30, 2016 | $2.22M | Mar 14, 2017 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.55M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $7.02M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $6.88M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $2.36M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $4.65M | Feb 26, 2024 |
| FY2020 | Dec 31, 2020 | $3.79M | Mar 29, 2021 |
| FY2020 | Sep 30, 2020 | $668.0K | Mar 29, 2021 |
| FY2020 | Jun 30, 2020 | $236.0K | Mar 29, 2021 |
| FY2020 | Mar 31, 2020 | $2.73M | Mar 29, 2021 |
| FY2020 | Dec 31, 2019 | $887.0K | Mar 29, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($258.76M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | ($157.86M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | ($141.43M) | Feb 25, 2026 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($287.37M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | ($195.08M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | ($154.54M) | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | ($115.23M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | ($71.24M) | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | ($63.35M) | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | ($55.03M) | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | ($156.44M) | Mar 29, 2021 |
| FY2019 | Dec 31, 2017 | ($121.53M) | Mar 26, 2020 |
| FY2018 | Dec 31, 2016 | ($132.92M) | Mar 7, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $245.07M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $163.55M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $118.01M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $82.26M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $53.31M | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $42.53M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $42.67M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $66.45M | Mar 29, 2021 |
| FY2019 | Dec 31, 2017 | $96.17M | Mar 26, 2020 |
| FY2018 | Dec 31, 2016 | $102.73M | Mar 7, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($210.95M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | ($157.78M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | ($107.29M) | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | ($103.73M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | ($60.91M) | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | ($40.40M) | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | ($46.42M) | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | ($75.24M) | Mar 29, 2021 |
| FY2019 | Dec 31, 2017 | ($99.93M) | Mar 26, 2020 |
| FY2018 | Dec 31, 2016 | ($113.04M) | Mar 7, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.71M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $1.92M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $1.82M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $1.83M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $1.25M | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $1.55M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $731.0K | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $813.0K | Mar 29, 2021 |
| FY2019 | Dec 31, 2017 | $1.79M | Mar 26, 2020 |
| FY2018 | Dec 31, 2016 | $2.75M | Mar 7, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $582.98M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $792.34M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $465.63M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $352.74M | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | $444.65M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $235.84M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $122.93M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $155.81M | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | $315.62M | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | $383.36M | Mar 7, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $55.82M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $45.34M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $36.46M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $26.53M | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | $25.18M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $26.48M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $28.91M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $31.75M | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | $79.26M | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | $117.93M | Mar 7, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $527.17M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $747.01M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $429.17M | Feb 25, 2026 |
| FY2025 | Dec 31, 2022 | $326.20M | Feb 25, 2026 |
| FY2024 | Dec 31, 2021 | $419.48M | Feb 27, 2025 |
| FY2023 | Dec 31, 2020 | $209.36M | Feb 26, 2024 |
| FY2022 | Dec 31, 2019 | $94.03M | Feb 28, 2023 |
| FY2021 | Dec 31, 2018 | $124.06M | Feb 28, 2022 |
| FY2020 | Dec 31, 2017 | $236.37M | Mar 29, 2021 |
| FY2019 | Dec 31, 2016 | $265.43M | Mar 26, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $90.98M | Mar 7, 2018 |
| FY2016 | Dec 31, 2016 | $90.98M | Mar 14, 2017 |
| FY2015 | Dec 31, 2015 | $8.97M | Feb 23, 2016 |
| FY2014 | Dec 31, 2014 | $8.97M | Feb 24, 2015 |
| FY2013 | Dec 31, 2013 | $8.97M | Mar 3, 2014 |
| FY2012 | Dec 31, 2012 | $8.97M | Mar 8, 2013 |
| FY2011 | Dec 31, 2011 | $8.97M | Mar 8, 2012 |
| FY2011 | Dec 31, 2010 | $8.97M | Mar 8, 2012 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.81B) | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | ($1.56B) | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | ($1.40B) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($1.26B) | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | ($1.14B) | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | ($1.07B) | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | ($1.01B) | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | ($962.44M) | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | ($812.52M) | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | ($719.49M) | Mar 7, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $28.87M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $28.36M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $34.81M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $29.43M | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | $39.14M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $43.84M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $11.23M | Mar 29, 2021 |
| FY2020 | Dec 31, 2018 | $24.31M | Mar 29, 2021 |
| FY2020 | Dec 31, 2017 | $40.29M | Mar 29, 2021 |
| FY2019 | Dec 31, 2016 | $42.46M | Mar 26, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (3) | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | (2) | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | (2) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | (1) | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | (2) | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | (3) | Feb 28, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (3) | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | (2) | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | (2) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | (1) | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | (2) | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | (3) | Feb 28, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 66.55M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | 66.37M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | 55.88M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | 47.20M | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | 46.73M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | 39.60M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | 16.97M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | 11.96M | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | 9.23M | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | 120.52M | Mar 7, 2018 |